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Abstract: Treatment of superficial venous thrombosis (SVT) has recently shifted as increasing 
evidence suggests a higher than initially recognized rate of recurrence as well as concomitant 
deep venous thrombosis. Traditional therapies aimed at symptom control and disruption of the 
saphenofemoral junction are being called into question. The incidence of deep venous throm-
bosis has been reported to be 6%–40%, with symptomatic pulmonary embolism occurring in 
2%–13% of patients. Asymptomatic pulmonary embolism is said to occur in up to one third of 
patients with SVT based on lung scans. The role of anticoagulation, including newer agents, is 
being elucidated, and surgical disruption of the saphenofemoral junction, while still an option for 
specific cases, is less frequently used as first-line treatment. The individual risk factors, including 
history of prior episodes of SVT, the presence of varicosities, and provoking factors including 
malignancy and hypercoagulable disorders, must all be considered to individualize the treatment 
plan. Given the potential morbidity of untreated SVT, prompt recognition and understanding of 
the pathophysiology and sequelae are paramount for clinicians treating patients with this disease. 
A personalized treatment plan must be devised for individual patients because the natural history 
varies by risk factor, presence or absence of DVT, and extent of involvement.
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Introduction
Superficial venous thrombosis (SVT) has received increased attention as more clini-
cians are recognizing the potential morbidity of untreated disease. Traditional therapies 
aimed at symptom control and disruption of the saphenofemoral junction (SFJ) are 
being called into question. The incidence of deep venous thrombosis (DVT) has been 
reported to be 6%–40%, with symptomatic pulmonary embolism occurring in 2%–13% 
of patients, and asymptomatic pulmonary embolism occurring in up to one third of 
patients with SVT based on lung scans.1 Given the potential morbidity of untreated 
SVT, prompt recognition and understanding of the pathophysiology and sequelae are 
paramount for clinicians treating patients with this disease. In addition, a review of cur-
rent strategies involving newer and developing treatment approaches is warranted.
Epidemiology and pathophysiology
SVT has been reported to occur in approximately 125,000 people yearly in the US.2 
However, this is generally believed to underestimate the true incidence, because 
many cases are unrecognized and unreported. Some studies demonstrate a higher 
prevalence in women overall, as well as an increased incidence with age in both males 
and females.3,4 Varicose veins, the most frequent predisposing factor, are   present in Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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up to 62% of patients with SVT.5,6 However, there is a wide 
range of predisposing conditions that have been delineated, 
including prolonged immobilization, trauma, obesity, 
hypercoagulable states, use of oral contraceptives or hor-
monal therapy, prior history of SVT or DVT, intravenous 
catheter use, malignancies, and autoimmune disorders.3,5,6 
In particular, patients identified with Behcet’s and Buerger’s 
disease have been highlighted in recent reviews as being 
particularly susceptible to SVT.7
SVT is characterized by the combination of thrombosis 
and inflammation in a superficial vein, and involves the great 
saphenous vein in up to 60%–80% of cases. Cases involving 
the small saphenous vein are next in frequency, occurring 
in 10%–20% of cases, followed by upper extremity veins. 
Thrombosis normally occurs as a sequelae of “phlebitis” or 
inflammation (not infection) of the vein. However, secondary 
“phlebitis” is also seen. The pathophysiology of SVT can 
be classified in terms of external trauma, internal direct 
endothelial trauma, vein wall inflammation, and primary 
hematologic changes. External trauma can result from direct 
external force or compression, either from blunt traumatic 
injury or externally applied dressings. A superficial vein 
exposed to external force can sustain endothelial damage with 
resulting edema and leukocyte activation that predisposes to 
thrombosis.8 Prominent varicose veins are both more likely 
to have decreased flow rates and venous stasis, as well as 
local external injury, contributing to the higher incidence 
of SVT.
Internal trauma involves a direct endothelial injury 
leading to activation of the same inflammatory response 
seen in external trauma, with similar outcomes. The inciting 
event is often related to routine intravenous procedures, 
including phlebotomy and intravenous infusions. The length 
of time a catheter is in place is related to the rate of SVT. 
In addition, infusion of hypertonic solutions can directly 
injure the endothelium. Commonly implicated drugs are 
diazepam and pentobarbitone, both of which can cause a 
chemical inflammation. Infusions in areas of slower venous 
return, such as in more distal veins, are also more likely to 
result in SVT. The patient most commonly presents with 
increasing pain and tenderness directly at the catheter site 
and erythema. The intravenous catheter can also serve as 
the nidus for suppurative superficial venous thrombosis. 
Thrombus which forms around a catheter tip thus becomes 
secondarily infected and can lead to sepsis.
Suppurative superficial venous thrombosis is characterized 
by pus at the injection site, a tender, erythematous extremity, 
and possibly systemic signs, including fever, leukocytosis, 
and hemodynamic compromise. Commonly cultured 
organisms include Staphylococcus aureus, Pseudomonas, 
Klebsiella, Enterococcus, Fusibacterium, and Candida.7 
Treatment requires prompt removal of the offending catheter, 
with drainage of any concomitant abscess and initiation of 
the appropriate intravenous antibiotics. Excision of the vein 
is not routinely necessary to treat the infection.
Vein wall inflammation can be a primary process, such 
as is seen in Buerger’s disease, or secondary to adjacent 
inflammatory changes. Buerger’s disease characteristically 
involves the small arteries and veins of the extremities, 
and biopsy findings of acute SVT involving all three layers 
of the vessel wall can confirm the diagnosis. Adjacent 
inflammation with resultant SVT can be due to trauma, 
infection, with the previously discussed septic thrombosis, 
or adjacent malignant disease. Because some tumors grow 
along the line of draining veins, this can result in SVT, 
and, in fact, malignancy is reported in up to 13%–18% of 
patients with SVT.8,9 Moreover, while the overall incidence 
of SVT in nonvaricose veins is much lower, the presence of 
SVT in nonvaricose veins may be associated with a risk of 
malignancy and, as such, merits additional evaluation as 
clinically indicated.10 Mondor’s disease is a specific entity that 
describes SVT of the thoracoepigastric vein of the breast and 
chest wall, most commonly associated with breast cancers or a 
hypercoagulable state. Nonsteroidal anti-inflammatory drugs 
and warm compresses are the recommended treatment in these 
cases, although the underlying process must also be evaluated. 
In males, Mondor’s disease has been used to describe SVT 
of the dorsal vein of the penis. If symptoms fail to improve 
with nonsteroidal anti-inflammatory drugs, resection of the 
dorsal penile vein is occasionally indicated.
Migratory SVT is characterized by repeated thromboses 
of superficial veins at varying sites. Described by Trousseau, 
when associated with cancer, migratory thrombophlebitis can 
occur years before a cancer diagnosis is made. Although it 
can also be seen with some of the vasculitides, a diagnosis 
of migratory SVT merits further investigation for an occult 
malignancy.8
Hypercoagulability may be associated with SVT in as many 
as 35% of patients.11 Hypercoagulable disorders associated 
with SVT include factor V Leiden mutation (the most 
common), 20210 A gene mutation, abnormal plasminogen, 
tissue plasminogen activator disorders, lupus anticoagulant, 
and anticardiolipin antibody syndrome. In addition, primary 
blood diseases, including polycythemia, thrombocythemia, 
and sickle cell disease, also have been implicated as strong 
risk factors for the development of SVT.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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We have previously reported that patients with a 
hypercoagulable disorder were significantly more likely to 
develop later acute DVT (P , 0.02), but that recurrence 
of SVT was not more likely. Patients with SVT should 
be subjected to a hypercoagulable workup using the same 
criteria as with acute DVT. In addition, screening for 
underlying diseases, such as malignancy or vasculitis, with 
mammography, colonoscopy, and appropriate radiologic 
studies is performed as needed.
The prevalence of associated acute DVT in patients 
presenting with SVT is estimated to 6.8%–40%.12–14 The 
reason for the range of associated acute DVT is because of 
the wide variation in study design, patient characteristics, 
symptomatic status, type of SVT, inpatient versus outpatient 
setting, indications, and whether or not any noninvasive 
testing was performed. A recent study of 788 patients with 
SVT links several factors as predictors for concurrent DVT. 
This includes, as expected, active cancer, as well as inpatient 
status, age greater than 75 years, and SVT of nonvaricose 
veins.15 In our previous experience with outpatients diag-
nosed with SVT, the incidence of acute DVT was 13%.16 
However, the incidence varied from 6.3% in patients with 
varicose veins, 33% in patients without varicose veins, and 
40% in patients with a previous history of DVT. The occur-
rence of concomitant pulmonary embolism is also variable, 
from 0.5% to 4% in symptomatic patients, increasing to 33% 
when a lung scan is performed.17,18
Diagnosis
Patients typically present with tender erythematous areas 
overlying a superficial vein. This may be warm to touch, 
with a palpable mass and surrounding edema. The vein may 
be visibly distended proximal to the thrombosis. Patients 
may exhibit signs of chronic venous disease, with visible 
varicosities, skin pigmentation, or palpable cords.
Pain can develop and progress quickly over several 
hours, and can be severe. The entire length of the great 
saphenous vein can be affected, or isolated segments can be 
involved. Isolated segments can be seen when associated 
with indwelling catheters. Direct trauma to the area is often 
elicited in the patient history, and can take the form of actual 
external trauma to the area or simply instrumentation with 
catheter placement and/or drug administration.
It is prudent to perform a duplex ultrasound scan in 
patients suspected of having SVT. Patients with catheter-
associated peripheral SVT of the upper limbs or minor SVT 
associated with direct trauma may not require a duplex 
ultrasound scan. The extent of superficial thrombosis should 
be documented, and evaluation for a concomitant DVT must 
be completed. Some patients warrant a hypercoagulable 
or malignancy evaluation particularly when SVT is not 
associated with instrumentation or varicosities. The clinical 
history, risk factors, and family history guide the extent of 
this evaluation, which may include simply screening for 
inherited thrombophilias or more extensive malignancy, or 
vasculitis screening.
Treatment algorithm
The vast majority of patients with SVT are treated symp-
tomatically with local heat, anti-inflammatory agents, and 
compression. Treatment of SVT is aimed at decreasing 
pain, decreasing inflammation, and preventing complica-
tions and recurrence. In cases secondary to an intravenous 
catheter or device, the offending foreign body must be 
removed. However, the treatment depends on the location, 
presence of concomitant acute DVT, first episode versus 
recurrence, presence or absence of varicose veins, and his-
tory of hypercoagulable disorders (Figure 1). As mentioned, 
the incidence of acute DVT is reported to be as high as 40%. 
Therefore, other than in patients with SVT associated with 
a local varix or an intravenous catheter or device, obtaining 
a duplex ultrasound scan of the extremity is helpful early in 
the course of treatment in most patients. Duplex ultrasound 
findings in acute DVT consist of noncompressibility of 
the vein, partial or absent color flow in the lumen, visual-
ization of luminal thrombus, absence of phasic variation 
with respiration and lack of augmentation of venous flow 
with calf compression and usually dilatation of the vein. 
In addition, special attention should be paid to the status 
of the SFJ both in terms of its relative distance from the 
thrombosed segment and whether the junction is incom-
petent. Patients with SVT in close proximity to the SFJ or 
saphenopopliteal junction are generally anticoagulated, 
even though the evidence for progression into the deep 
venous system is weak. Patients with SVT and varicose 
veins and reflux demonstrated by duplex ultrasound scan 
may be initially treated nonoperatively, although a large 
number will require surgery. Indeed, some authors strongly 
advocate considering surgery first in cases of SVT involv-
ing the axial veins with documented reflux of the SFJ. In 
order to minimize morbidity and loss of work, it may be 
more expeditious to remove the affected saphenous vein 
along with the varicose veins. In patients without varicose 
veins, the probability of an underlying thrombophilic 
disorder is high, and investigation is necessary prior to the 
use of anticoagulants.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Newer and evolving treatment 
approaches
The traditional approach for the vast majority of patients has 
focused on alleviating symptoms with warm compresses, non-
steroidal anti-inflammatory drugs, and compression   garments 
when necessary. Frequent ambulation rather than bed rest 
is also advised. A change in strategy in managing certain 
patients with specific problems associated with SVT has 
materialized in recent reports. A personalized, individualized 
treatment plan seems to be the best approach towards this 
group of patients because the variation in presentation, risk 
factors, and extent of involvement is considerable.
SVT of the great saphenous vein
We have reported that almost 82% of outpatients with SVT 
were found to have involvement of the superficial axial veins.16 
SVT in the superficial axial veins (great saphenous vein or small 
saphenous vein) is generally considered to   warrant aggressive 
treatment with low molecular weight heparin to prevent exten-
sion into the deep venous system, particularly if the SVT is close 
to the junction with the common femoral or popliteal veins. 
Chengelis et al reported a 24% incidence of progression to DVT 
in 263 patients with proximal great saphenous vein involve-
ment or SFJ involvement (14%) who were not treated with 
anticoagulants.19 The majority (85.7%) of DVT in this subgroup 
Superficial venous
thrombosis (lower 
extremity)
Associated with 
DVT
Anticoagulation Below SFJ
Without varicose
veins
With varicose veins
Consider surgical
intervention
No SFJ/SPJ reflux
SFJ/SPJ reflux on
duplex ultrasound
Hypercoagulable
disorder investigation
Negative, treat
symptoms
Positive, treat
underlying disorder,
possible long term
anticoagulation
Selective
anticoagulation,
surgery
Symptomatic
treatment
Up to SFJ
No associated
DVT
Figure 1 Management plan for superficial venous thrombosis of the lower extremity.
Abbreviations: DVT, deep venous thrombosis; SFJ, saphenofemoral junction; SPJ, saphenopopliteal junction.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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was observed to develop by extension through the SFJ, and 
the remaining extended via thigh perforating veins. The group 
with distal saphenous vein or variceal involvement only had a 
4% incidence of DVT prompting the authors to recommend 
anticoagulants for all patients with proximal great saphenous 
vein or SFJ thrombus. The POST Study Group evaluated 
844 patients with SVT, 25% of whom had concomitant DVT. 
Of the 600 patients who initially presented without DVT or 
pulmonary embolism, 10.2% developed some thromboembolic 
complications within the three-month follow-up period.20
In another series of 20 selected patients with SVT of the 
great saphenous vein within 1 cm of the SFJ, there was a 40% 
incidence of concurrent acute DVT.13 Lohr et al reported on 
43 patients who had SVT of the great saphenous vein within 
3 cm of the SFJ by duplex ultrasound scan.21 Prandoni et al 
randomized patients with thrombus extending to within 
3 cm of the SFJ to either therapeutic (n = 83) or prophylactic 
(n = 81) doses of subcutaneous nadroparin for 30 days, with 
extension defined as progression of the SVT by at least 2 cm 
and closer than 3 cm from the SFJ.22 After treatment, two 
DVT events occurred in the prophylactic group and three in 
the therapeutic group, with only one symptomatic pulmonary 
embolism in the therapeutic group. Overall, 8.6% of patients 
in the prophylactic group and 7.2% in the treatment group 
developed either SVT progression or venous thromboembolic 
complications during the three-month follow-up period.
A meta-analysis of largely retrospective studies by 
Sullivan et al suggests that anticoagulation for the treatment 
of above-knee great saphenous vein involvement appears 
to be a reasonable option.23 A recent randomized, double-
blind trial in over 3000 patients demonstrated a reduction 
of both pulmonary embolism and DVT from 1.3% to 
0.2% (P , 0.001) for patients with SVT treated with 
fondaparinux versus placebo once a day for 45 days. Bleeding 
complications were similar in both groups.24 Indeed, Kitchens 
emphasizes that treatment of SVT is equivalent to that for 
venous thromboembolism with recommendations of full 
anticoagulation and further evaluation and imaging only if 
treatment would be altered, using the same considerations in 
evaluating SVT as are routinely used for DVT.25 Preliminary 
results suggest a lower recurrence rate, but whether 
anticoagulation enhances patency of the great saphenous vein 
allowing for later use as a conduit remains unresolved.
Recurrence of SVT
Recurrence of SVT is reported in 15%–20% of patients.26 
Hafner et al27 in a series of 324 patients reported a prior 
history of similar episodes in 15% of patients. Ascer et al28 
described a previous history of SVT in 20% in their series of 
20 patients. The Austrian Study on Recurrent Venous Throm-
boembolism reported a 30-month follow-up of 615 patients 
with venous thromboembolism treated for three months with 
anticoagulants to look at the incidence and various factors that 
led to SVT.29 The overall incidence of recurrence in this group 
was 7.5%. Patients who developed SVT were older, were fol-
lowed up for longer, had a higher body mass index, and had 
a higher level of factor VIII (but not factor V Leiden). The 
recurrence rate obviously varies with the risk factors in the 
study cohort. Our previous report identified a 6% recurrence 
rate in 60 outpatients with SVT, and these episodes occurred 
at a mean of 57.8 days (standard deviation 50.09, median 
39 days).15 Recurrent SVT was much more likely in patients 
with thrombosis of the tributaries as compared with patients 
without thrombosis of tributaries (P , 0.0008).
Randomized studies with low 
molecular weight heparin
There are multiple reasons for considering anticoagulants 
as a treatment option in patients with acute SVT. The most 
common indication is the presence of or increased risk of asso-
ciated acute DVT/pulmonary embolism due to the location of 
SVT. In such cases, prophylaxis for about four weeks is often 
recommended.1 In a multicenter study of 117 patients random-
ized between fixed-dose low molecular weight heparin, dose-
monitored low molecular weight heparin, and oral naproxen 
for six days, local heat and redness were less in both the low 
molecular weight heparin groups compared with naproxen. In 
addition, both low molecular weight heparin groups had less 
persistence of signs and symptoms at eight weeks.30 In another 
large randomized study, 427 patients with acute SVT of the 
legs were randomized to a fixed dose of enoxaparin 40 mg, 
enoxaparin 1.5 mg/kg body weight, an oral nonsteroidal anti-
inflammatory drug, ie, tenoxicam 20 mg, or placebo once daily 
for 8–12 days.31 Compared with placebo, the active treatment 
groups showed a much lower incidence of acute DVT and 
SVT by day 12 (placebo 30.6% versus 8.3% for fixed-dose 
enoxaparin, 6.9% for weight-based enoxaparin, and 14.9% 
for tenoxicam). At three months, the active treatment groups 
still retained an advantage versus placebo for combined DVT 
and SVT. Overall, there is evidence indicating that both low 
molecular weight heparin and nonsteroidal anti-inflammatory 
drugs reduce the progression of SVT or recurrence.
Current role of surgery
One of the earliest and largest experiences with SVT 
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with a recurrence rate of only 4.3% and a mean follow-up 
of five years. Interestingly, two thirds of these patients 
received postoperative anticoagulants.33 The safety of surgical 
intervention was also established by Husni and Williams, who 
reported 135 patients with SVT treated surgically with no 
postoperative pulmonary embolism.26 Sullivan et al reviewed 
several series of patients with SVT of the above-knee great 
saphenous vein and compared the outcome of treatment with 
anticoagulation, ligation of the SFJ, and ligation and stripping 
of the great saphenous vein.23 They concluded that ligation 
and stripping of the great saphenous vein was superior to 
ligation alone or anticoagulation in terms of rapid symptom 
relief. Anticoagulation was noted to be somewhat superior 
for minimizing complications and preventing subsequent 
DVT and pulmonary embolism.
A randomized trial with 70 patients in each of six groups 
showed that complete vein stripping or treatment with 
unfractionated heparin, low molecular weight heparin, or 
warfarin were superior to compression alone or in addition 
to flush ligation of the saphenous vein for the end point of 
SVT extension at three months.34 Another trial compared 
enoxaparin 1 mg/kg twice daily for one week, and then daily 
for three weeks with saphenofemoral ligation performed 
under local anesthesia with a follow-up of six months.35 
Pulmonary embolism occurred in two patients (6.7%) in the 
surgery group versus no venous thromboembolism in the 
enoxaparin group. SVT occurred in 10% of the enoxaparin 
group and in one patient (3.3%) in the surgery group. 
Similar rates of SVT progression but higher rates of venous 
thromboembolism and complications were observed with 
surgical therapy compared with anticoagulation for SVT.23
The use of simple ligation or disconnection of the SFJ 
or saphenopopliteal junction for thrombus close to the SFJ/
saphenopopliteal junction, contraindication to anticoagulants, 
or progression as an acute measure despite anticoagulant 
therapy is no longer relevant for patients who need surgical 
intervention. In most cases, ligation and concomitant excision 
of the affected vein with the thrombosed vein branches, if 
feasible, can be safely performed. The complete operation 
can remove existing varicosities, provide cosmetic relief, 
relieve pain, prevent recurrences, and shorten the recovery 
time associated with periods of anticoagulation, with minimal 
morbidity.23
Conclusion
The most recent American College of Chest Physicians guide-
lines state “For patients with spontaneous superficial vein 
thrombosis, we suggest prophylactic or intermediate doses 
of low molecular weight heparin (Grade 2B) or intermediate 
doses of UFH (Grade 2B) for at least 4 weeks.”32 The decision 
to use anticoagulant treatment for patients with SVT is not 
controversial in those patients with known thrombophilic 
disorders, continued symptoms, progression, and recur-
rent episodes. Patients without clinical risk factors such as 
immobilization, obesity, malignancy, or hormonal therapy, 
or immobilization and associated SVT certainly are at lower 
risk to develop complications of venous thromboembolism 
and therefore a less aggressive stance may be justified. If the 
axial great saphenous vein or small saphenous vein system 
is involved but the thrombus is not in proximity to the SFJ 
or saphenopopliteal junction, standard measures including 
heat, anti-inflammatory drugs, and ambulation are advised. 
For SVT at or close to the SFJ, the general recommendation 
(without solid evidence) is low molecular weight heparin. 
A repeat duplex ultrasound scan may be advisable in almost 
all circumstances if the symptoms persist or worsen. The role 
of surgical excision, or exclusion of the vein, becomes impor-
tant when dealing with refractory or recurrent cases of SVT. 
However, surgery does not address any concomitant DVT, 
a phenomenon which has been increasingly appreciated in 
recent literature. This review of the literature emphasizes the 
wide variation in presentation, risk factors, associated DVT, 
or pulmonary embolism, and extent of local involvement 
of the superficial axial veins. It becomes clear that a more 
personalized, individualized approach to the patient with 
SVT is necessary.
Future directions
Because the reported incidence of acute DVT in patients 
with SVT can be as high as 40%, a multicenter, prospective, 
randomized study is needed to clarify the role of anticoagulant 
therapy as well as the optimal dosing and duration of 
treatment. In patients with recurrent SVT, such as the patient 
population with thrombophilic disorders, the use of the newer 
oral anticoagulants will need to be clarified. Even though 
there are some studies comparing nonoperative treatment 
and surgical intervention, we need a large multicenter study 
to look at the recurrence rate, morbidity, and cost-benefit 
analysis to elucidate the exact role of surgical intervention. 
If surgical therapy is beneficial, which specific groups should 
be considered? These unresolved issues are prime targets 
for future research to allow for safer and more cost-efficient 
management of patients with SVT.
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